Comparative Pharmacology
Head-to-head clinical analysis: LASIX ONYU versus URESE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LASIX ONYU versus URESE.
LASIX ONYU vs URESE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lasix (furosemide) inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption.
Urease inhibitor; reduces bacterial conversion of urea to ammonia, lowering urine pH and ammonia concentration.
Furosemide 20-80 mg IV/PO once or twice daily; max 600 mg/day for IV, 80 mg/day for PO.
Oral: 20 mg once daily. May increase to 40 mg once daily if needed after 4 weeks. Maximum: 40 mg/day.
None Documented
None Documented
1.5-2.0 hours in normal renal function; prolonged to 10-15 hours in severe renal impairment (CrCl <10 mL/min); clinically significant accumulation risk with repeated dosing in renal disease.
4-6 hours; prolonged in renal impairment (up to 12-15 hours in anuria).
Primarily renal (50-80% as unchanged drug); biliary/fecal (20-30%); non-renal clearance accounts for up to 20%.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Category C
Category C
Loop Diuretic
Loop Diuretic